Skip to main content

Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

16.16€

0.29 / 1.83%

2025-08-13 11:16 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

33,065,845
(February 21, 2025)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Oscar Haffen Lamm

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Claire Deray

Documentation

June 2025

Corporate presentation

2025

CSR report

Latest news

Notice of the 2025 Annual General Meeting Published
August 4, 2025

Notice of the 2025 Annual General Meeting Published

UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
July 30, 2025

UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025

Medincell Proposes Board Appointments of Dr. Sharon Mates and Dr. Charles Kunsch
July 29, 2025

Medincell Proposes Board Appointments of Dr. Sharon Mates and Dr. Charles Kunsch

Press Release: Consolidated Annual Financial Results
June 17, 2025

Press Release: Consolidated Annual Financial Results

Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation
May 28, 2025

Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap